# Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

> **NCT00050232** · PHASE3 · COMPLETED · sponsor: **Avanir Pharmaceuticals** · enrollment: 96 (—)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** AVP-923

## Key facts

- **NCT ID:** NCT00050232
- **Lead sponsor:** Avanir Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2004-06
- **Final completion:** 2004-06
- **Target enrollment:** 96 (—)
- **Last updated:** 2016-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050232, "Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00050232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*